Tirzepatide doses for weight loss: the full picture

The biggest myth: higher doses work better because they're stronger

It is tempting to think of the six strengths as a simple potency ladder, and that landing on the highest rung as fast as possible will produce the best results. That is not quite how it works. The 15 mg dose does produce the greatest average weight loss in trial data, but the doses below it serve a specific purpose: they train your gut to handle the medicine without overwhelming it with nausea or vomiting. Rush the schedule and you are more likely to abandon treatment early, not to get ahead of it.

What the SURMOUNT-1 trial actually showed (published in the New England Journal of Medicine) is that adults at the 10 mg and 12.5 mg levels also achieved meaningful, clinically significant weight reduction. The 15 mg figure of roughly 20–21% average loss gets the headlines, but the full titration journey contributed to that outcome. For many people, a lower maintenance dose is the right clinical endpoint because it produces good results with fewer side effects. That is a prescriber's judgement, not a default setting.

The common side effects of tirzepatide (nausea, loose stools, indigestion, reduced appetite that can tip into under-eating) are almost always at their most noticeable right after a dose step up, and tend to ease within a week or two as the body adjusts. Slowing the schedule is sometimes the right clinical move, and that decision belongs to your prescriber.

What each dose is actually doing

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, which together reduce appetite, slow gastric emptying and influence blood-sugar regulation. That dual mechanism is what separates it from single-pathway medicines. But the receptor response scales with dose, which is why the titration steps exist: the 2.5 mg pen is not expected to produce significant appetite suppression in most people. Its job is adjustment. By the time someone reaches 5 mg (a step many people stay on longer than they expected) appetite reduction is often noticeable.

Each subsequent step tends to deepen that effect. The doses of tirzepatide for weight loss do not work like an on/off switch; they work more like a dial being turned slowly, with the body recalibrating at each level. That is why rushing from 2.5 mg to 10 mg in a matter of weeks is both clinically inadvisable and outside the licensed schedule. The BNF entry for tirzepatide sets out the licensed dose-escalation framework that prescribers follow.

Storage matters at every dose: pens are kept refrigerated between 2–8°C. For the exact room-temperature window (useful when you are travelling or ordering around a bank holiday) refer to the Patient Information Leaflet that comes with your pen, since that figure should never be guessed at.

Which dose you end up on, and who decides

There is no single "right" maintenance dose for tirzepatide. The licence covers adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related health condition, but eligibility and the eventual target dose are two different things. A prescriber considers your starting weight, how you are tolerating each step, any relevant medical history and your response to treatment so far. Some people reach 15 mg and stay there; others find 10 mg or 12.5 mg is where they get the best balance of effect and tolerability.

If you are curious about how the highest licensed dose is evaluated and what the trial evidence looks like at that level, the detail on the 15 mg dose is worth reading before your consultation. If you are early in the journey and the 2.5 mg starting step feels confusing given how small it is, there is a fuller explanation of exactly what that first pen is doing.

On the cost side, the dose you are prescribed affects what you pay, since each pen is a four-week supply. A consultation with a prescriber is the starting point for understanding which strength is clinically appropriate for you, and what that costs through a regulated, GPhC-registered pharmacy like nume. To put private pricing in context, the treatment overview covers how the private market works and what a legitimate all-in price should include.

The 7.5 mg step and why it gets skipped in conversation

Most public discussion of tirzepatide doses clusters around the bookends: the 2.5 mg starter and the 15 mg ceiling. The middle steps (5, 7.5, 10 and 12.5 mg) get less attention, which is odd given that most people spend the majority of their treatment time moving through them. The 7.5 mg step in particular tends to be where some people plateau for longer than expected, either because they are tolerating the dose well and their prescriber is in no rush, or because the next step up is being approached cautiously after a difficult period on 5 mg.

That is not a problem. Spending an extra month or two at a given dose (say, because you ordered at the end of the month, or a bank holiday shifted your delivery) does not reset your progress. The medicine continues to work at the current level. What matters is not the speed of titration but consistent, supervised use with clinical re-review at each repeat. Our prescribers at nume review every repeat order before it is dispensed, partly for this reason: each review is a checkpoint, not an automatic renewal.

If you want more on the 5 mg dose specifically, including how long most people stay there before moving up, the dosage detail at that strength covers the evidence. And for a broader view of the medicine before going into dose specifics, the Mounjaro 5mg page is a practical reference point.